Proteome Sciences PLC Change of Auditor (6403B)
2022年10月4日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMPRM
RNS Number : 6403B
Proteome Sciences PLC
04 October 2022
4 October 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Change of Auditor
Proteome Sciences Plc ("Proteome Sciences", or "the Company")
announces that the Board has approved the appointment of Cooper
Parry Group Limited (Cooper Parry) as the Group's new external
auditor, and that BDO LLP ("BDO") has resigned as the Group's
auditor.
Cooper Parry will conduct the audit of the Group's financial
statements for the financial period to 31 December 2022 and a
proposal to re-appoint Cooper Parry as auditors of the Group will
be subject to the approval of shareholders at the 2023 Annual
General Meeting.
BDO has been the auditor for the Company since 2014 and we thank
them for their services over this time. BDO has confirmed to the
Company that there are no matters connected with their ceasing to
hold office that need to be brought to the attention of the members
or creditors of the Company for the purposes of section 519 of the
Companies Act 2006.
- Ends -
For further information:
Proteome Sciences plc
Dr Mariola Soehngen, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Abdelghani Omari, Chief Financial
Officer
Dr Ian Pike, Chief Scientific
Officer
Richard Dennis, Chief Commercial
Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale/ Jeremy Porter Tel: +44 (0)20 3328 5656
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R) MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in Cobham, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFFFIFILLVIIF
(END) Dow Jones Newswires
October 04, 2022 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 11 2024 まで 12 2024
Proteome Sciences (AQSE:PRM.GB)
過去 株価チャート
から 12 2023 まで 12 2024